Regulation of inflammasomes by ubiquitination

Cellular and Molecular Immunology

Volumn 13, Issue 6, 2016, Pages 722-728

  Bednash, Joseph S ^a   Mallampalli, Rama K ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Deubiquitinase; E3 ligase; Inflammasome; Innate immunity; Ubiqutin

Indexed keywords

ADAPTOR PROTEIN; APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN CONTAINING A CASPASE ACTIVATION AND RECRUITMENT DOMAIN PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; DEUBIQUITINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CYTOKINE RELEASE; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UBIQUITINATION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; METABOLISM;

ANIMALS; HUMANS; INFLAMMASOMES; MODELS, BIOLOGICAL; UBIQUITIN; UBIQUITINATION;

EID: 84994620550     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.15     Document Type: Review

References (62)

1. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
2. Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev 2015; 265: 6-21.
3. Harton JA, Linhoff MW, Zhang J, Ting JP. Cutting edge: CATERPIL-LER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 2002; 169: 4088-4093.
4. Cridland JA, Curley EZ, Wykes MN, Schroder K, Sweet MJ, Roberts TL et al. The mammalian PYHIN gene family: phylogeny, evolution and expression. BMC Evol Biol 2012; 12: 140.
5. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426.
6. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-232.
7. Poyet JL, Srinivasula SM, Tnani M, Razmara M, Fernandes-Alnemri T, Alnemri ES. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem 2001; 276: 28309-28313.
8. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458: 509-513.
9. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458: 514-518.
10. Burckstummer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10: 266-272.
11. Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L et al. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 2012; 36: 464-476.
12. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014; 157: 1013-1022.
13. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14: 1590-1604.
14. Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 2014; 156: 1193-1206.
15. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
16. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107: 1062-1073.
17. Hoffman HM, Wanderer AA. Inflammasome and IL-1beta-mediated disorders. Curr Allergy Asthma Rep 2010; 10: 229-235.
18. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005; 6: 79-87.
19. Sasaki K, Iwai K. Roles of linear ubiquitinylation, a crucial regulator of NF-kappaB and cell death, in the immune system. Immunol Rev 2015; 266: 175-189.
20. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
21. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
22. Weathington NM, Sznajder JI, Mallampalli RK. The emerging role of the ubiquitin proteasome in pulmonary biology and disease. Am J Respir Crit Care Med 2013; 188: 530-537.
23. Chen BB, Coon TA, Glasser JR, McVerry BJ, Zhao J, Zhao Y et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat Immunol 2013; 14: 470-479.
24. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006; 25: 6680-6684.
25. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998; 95: 749-758.
26. Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T. Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway. Biochimie 2001; 83: 351-356.
27. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
28. Bryant C, Fitzgerald KA. Molecular mechanisms involved in inflamma-some activation. Trends Cell Biol 2009; 19: 455-464.
29. Weng L, Mitoma H, Trichot C, Bao M, Liu Y, Zhang Z et al. The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation. J Immunol 2014; 193: 3676-3682.
30. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113: 2324-2335.
31. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183: 787-791.
32. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287: 36617-36622.
33. Fernandes-Alnemri T, Kang S, Anderson C, Sagara J, Fitzgerald KA, Alnemri ES. Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome. J Immunol 2013; 191: 3995-3999.
34. Ghonime MG, Shamaa OR, Das S, Eldomany RA, Fernandes-Alnemri T, Alnemri ES et al. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function. J Immunol 2014; 192: 3881-3888.
35. Schroder K, Sagulenko V, Zamoshnikova A, Richards AA, Cridland JA, Irvine KM et al. Acute lipopolysaccharide priming boosts inflamma-some activation independently of inflammasome sensor induction. Immunobiology 2012; 217: 1325-1329.
36. Duong BH, Onizawa M, Oses-Prieto JA, Advincula R, Burlingame A, Malynn BA et al. A20 restricts ubiquitination of pro-interleukin-1beta protein complexes and suppresses NLRP3 inflammasome activity. Immunity 2015; 42: 55-67.
37. Ortiz-Lazareno PC, Hernandez-Flores G, Dominguez-Rodriguez JR, Lerma-Diaz JM, Jave-Suarez LF, Aguilar-Lemarroy A et al. MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-kappaB and activator protein-1. Immunology 2008; 124: 534-541.
38. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013; 49: 331-338.
39. Lopez-Castejon G, Luheshi NM, Compan V, High S, Whitehead RC, Flitsch S et al. Deubiquitinases regulate the activity of caspase-1 and interleukin-1beta secretion via assembly of the inflammasome. J Biol Chem 2013; 288: 2721-2733.
40. Han S, Lear TB, Jerome JA, Rajbhandari S, Snavely CA, Gulick DL et al. Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase. J Biol Chem 2015; 290: 18124-18133.
41. Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 2015; 160: 62-73.
42. Yen H, Sugimoto N, Tobe T. Enteropathogenic Escherichia coli uses NleA to inhibit NLRP3 inflammasome activation. PLoS Pathog 2015; 11: e1005121.
43. Li M, Shi X, Qian T, Li J, Tian Z, Ni B et al. A20 overexpression alleviates pristine-induced lupus nephritis by inhibiting the NF-kappaB and NLRP3 inflammasome activation in macrophages of mice. Int J Clin Exp Med 2015; 8: 17430-17440.
44. Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 2014; 512: 69-73.
45. Suzuki S, Mimuro H, Kim M, Ogawa M, Ashida H, Toyotome T et al. Shigella IpaH7.8 E3 ubiquitin ligase targets glomulin and activates inflammasomes to demolish macrophages. Proc Natl Acad Sci USA 2014; 111: E4254-E4263.
46. Kumar Y, Radha V, Swarup G. Interaction with Sug1 enables Ipaf ubiquitination leading to caspase 8 activation and cell death. Biochem J 2010; 427: 91-104.
47. Tokunaga F, Iwai K. [Involvement of LUBAC-mediated linear polyubiquitination of NEMO in NF-kappaB activation]. Tanpakushitsu Kakusan Koso 2009; 54: 635-642.
48. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 2011; 471: 633-636.
49. Rodgers MA, Bowman JW, Fujita H, Orazio N, Shi M, Liang Q et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J Exp Med 2014; 211: 1333-1347.
50. Gurung P, Lamkanfi M, Kanneganti TD. Cutting edge: SHARPIN is required for optimal NLRP3 inflammasome activation. J Immunol 2015; 194: 2064-2067.
51. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012; 13: 255-263.
52. Guan K, Wei C, Zheng Z, Song T, Wu F, Zhang Y et al. MAVS promotes inflammasome activation by targeting ASC for K63-linked ubiquitina-tion via the E3 ligase TRAF3. J Immunol 2015; 194: 4880-4890.
53. Ainscough JS, Frank Gerberick G, Zahedi-Nejad M, Lopez-Castejon G, Brough D, Kimber I et al. Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome. J Biol Chem 2014; 289: 35582-35592.
54. Niebler M, Qian X, Höfler D, Kogosov V, Kaewprag J, Kaufmann AM et al. Post-translational control of IL-1beta via the human papilloma-virus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog 2013; 9: e1003536.
55. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015; 21: 677-687.
56. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009; 187: 61-70.
57. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
58. Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y et al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 2014; 346: 1000-1003.
59. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem 2010; 285: 9792-9802.
60. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21: 263-269.
61. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011; 34: 213-223.
62. Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21: 248-255.